Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HDL‐C Levels Associated with Harmful CKD Progression

By LabMedica International staff writers
Posted on 17 Apr 2019
Serum high‐density lipoprotein (HDL) has traditionally been considered to be protective against cardiovascular disease in the general population. HDL exerts an antiatherogenic effect through reverse cholesterol transport, a multiorgan process that removes excess cholesterol from lipid‐laden macrophages and peripheral tissue.

Chronic kidney disease (CKD) has become a serious health concern worldwide, given the high burden of cardiovascular events and death in patients with this condition. Dyslipidemia is common in patients with CKD and is characterized by lower levels of HDL‐C and higher levels of triglyceride and oxidized low‐density lipoprotein cholesterol.

A team of scientists at Yonsei University (Seoul, South Korea) carried out a prospective nationwide cohort study investigating various clinical courses and risk factors for the progression of CKD in Korean patients. Patients, aged between 20 and 75 years, with CKD stages from 1 to 5 before dialysis, who voluntarily provided informed consent, were enrolled from nine tertiary‐care general hospitals throughout Korea between June 2011 and February 2016. There were 2,168 patients were included in the final analysis.

After overnight fasting, blood samples were collected for measurements of creatinine. Other biochemical analyses, including lipid profiles, were done at the local laboratory of each participating center. Most laboratory parameters were measured every six months in the first year and annually thereafter, including complete blood cell count, fasting glucose, blood urea nitrogen, creatinine, albumin, calcium, and phosphorus. C‐reactive protein, iron profiles (including total iron‐binding capacity and serum ferritin), and lipid profiles (including triglyceride, HDL‐C, and low‐density lipoprotein cholesterol) were measured repeatedly after one year and biennially thereafter. The team used a creatinine method that requires calibration traceable to isotope dilution mass spectrometry, and estimated glomerular filtration rate (eGFR) was calculated using the CKD. Urine samples were analyzed for proteinuria measurement. Urine albumin/creatinine ratio was calculated as the urine albumin concentration divided by the urine creatinine concentration (mg/g).

The team reported that the primary outcome was the composite of a 50% decline in eGFR from baseline or end‐stage renal disease. The secondary outcome was the onset of end‐stage renal disease. During a median follow‐up of 3.1 years, the primary outcome occurred in 335 patients (15.5%). In a fully adjusted Cox model, the lowest category with HDL‐C of <30 mg/dL (hazard ratio, 2.21) and the highest category with HDL‐C of ≥60 mg/dL (hazard ratio, 2.05) were associated with a significantly higher risk of the composite renal outcome, compared with the reference category with HDL‐C of 50 to 59 mg/dL. This association remained unaltered in a time‐varying Cox analysis. Furthermore, consistent findings were obtained in a secondary outcome analysis for the development of end‐stage renal disease.

The authors concluded that an U‐shaped association was observed between serum HDL‐C levels and adverse renal outcomes in this large cohort of patients with CKD. The findings suggest that both low and high serum HDL‐C levels may be detrimental to patients with non-dialysis CKD. The study was published on March 12, 2019, in the Journal of the American Heart Association.

Related Links:
Yonsei University


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.